Printer-friendly versionPrinter-friendly version

2016 - Reference list of hepatitis publications of the VHPB board members

2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV.
Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, Volant J, Dhumeaux D, Yazdanpanah Y; Viral Hepatitis Testing Experts group.
Liver Int. 2016; 36(10):1442-9. doi: 10.1111/liv.13135.
Key Role of Sequencing to Trace Hepatitis A Viruses Circulating in Italy During a Large Multi-Country European Foodborne Outbreak in 2013.
Bruni R, Taffon S, Equestre M, Chionne P, Madonna E, Rizzo C, Tosti ME, Alfonsi V, Ricotta L, De Medici D, Di Pasquale S, Scavia G, Pavoni E, Losio MN, Romanò L, Zanetti AR, Morea A, Pacenti M, Palù G, Capobianchi MR, Chironna M, Pompa MG, Ciccaglione AR; Italian National Task Force on Hepatitis A.
PLoS One 11(2): e0149642.
Markers of Protection in Children and Adolescents Six to Fourteen Years After Primary Hepatitis B Vaccination in Real Life: A Pilot Study.
Brunskole Hummel I, Huber B, Wenzel JJ, Jilg W.
Pediatr Infect Dis J. 2016; 35(3):286-91. doi: 10.1097/INF.0000000000000994.
Characteristics of immune memory 10-15 years after primary hepatitis B vaccination.
Brunskole Hummel I, Zitzmann A, Erl M, Wenzel JJ, Jilg W.
Vaccine. 2016 Jan 27;34(5):636-642. doi: 10.1016/j.vaccine.2015.12.033.
Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care.
Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, Hézode C, Pawlotsky JM.
Clin Microbiol Infect. 2016; pii: S1198-743X(16)00025-2. doi: 10.1016/j.cmi.2016.01.009.
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B.
Front Pharmacol. 2016; 7: 197.
Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y.
J Viral Hepat. 2016; 23(10):767-79. doi: 10.1111/jvh.12546.
Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns.
Ederth J, Jern C, Norder H, Magnius L, Alm E, Rognsvåg BK, Sundin CG, Brytting M, Esbjörnsson J, Mild M.
Infect Ecol Epidemiol. 2016; 6:30670. doi: 10.3402/iee.v6.30670. eCollection 2016.
Hepatitis E in Israel: A nation-wide retrospective study.
Erez-Granat O, Lachish T, Daudi N, Shouval D, Schwartz E.
World J Gastroenterol. 2016; 22(24): 5568-5577.
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).
Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group.
Hepatology. 2016; 64(4):1136-47. doi: 10.1002/hep.28702.
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group.
Gastroenterology. 201; pii: S0016-5085(16)35070-3. doi: 10.1053/j.gastro.2016.09.009.
Outbreaks of hepatitis A associated with immigrants travelling to visit friends and relatives.
Godoy P, Broner S, Manzanares-Laya S, Martínez A, Parrón I, Planas C, Sala-Farré MR, Minguell S, de Olalla PG, Jané M, Domínguez A, Working Group for the Study of Hepatitis A in Catalonia.
Journal of Infection 2016; 72:112-129.
National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
Gvinjilia L, Nasrullah M, Sergeenko D, Tsertsvadze T, Kamkamidze G, Butsashvili M, Gamkrelidze A, Imnadze P, Kvaratskhelia V, Chkhartishvili N, Sharvadze L, Drobeniuc J, Hagan L, Ward JW, Morgan J, Averhoff F.
MMWR Morb Mortal Wkly Rep. 2016; 65(41): 1132-1135.
Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen.
Hézode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, Ruiz I, Roudot-Thoraval F, Mallat A, Féray C, Pawlotsky JM.
Hepatology. 2016; doi: 10.1002/hep.28491.
Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
Hutin, Y. J. and S. Z. Wiktor.
Gut.2016.
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
Isakov V, Zhdanov K, Kersey K, Svarovskaia E, Massetto B, Zhu Y, Knox SJ, Bakulin I, Chulanov V.
Antivir Ther. 2016; 21(8): 671-678.
Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia.
Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA; P08160 Trial Investigators.
World J Hepatol. 2016 Feb 28;8(6):331-9. doi: 10.4254/wjh.v8.i6.331.
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype 1 and 3 HCV infection: results from a Russian Phase IIIb study.
Isakov V, Zhdanov K, Kersey K, Svarovskaia E, Massetto B, Zhu Y, Knox SJ, Bakulin I, Chulanov V.
Antivir Ther. 2016 Jul 4. doi: 10.3851/IMP3065.
The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study.
Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, Krajden M, Ward JW, Harrigan PR, Montaner JS, Poon AF.
Lancet Infect Dis. 2016; 16(6): 698-702.
The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.
Klevens RM, Canary L, Huang X, Denniston MM, Yeo AE, Pesano RL, Ward JW, Holmberg S.
Clin Infect Dis. 2016; 63(8): 1049-1055.
Trends in Injection Drug Use Among High School Students, U.S., 1995-2013.
Klevens RM, Jones SE, Ward JW, Holtzman D, Kann L.
Am J Prev Med. 2016 Jan;50(1):40-6. doi: 10.1016/j.amepre.2015.05.026. Epub 2015 Aug 24.
Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014.
Koneru A, Nelson N, Hariri S, Canary L, Sanders KJ, Maxwell JF, Huang X, Leake JA, Ward JW, Vellozzi C.
MMWR Morb Mortal Wkly Rep. 1016; 65(28): 705-710.
Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
Manor Y, Lewis M, Ram D, Daudi N, Mor O, Savion M, Kra-Oz Z, Shemer Avni Y, Sheffer R, Shouval D, Mendelson E.
J Infect Dis. 2016.
A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care.
Marinho RT, Costa A, Pires T, Raposo H, Vasconcelos C, Polónia C, Borges J, Soares M, Vilar G, Nogueira AM; LIGUE-C Investigators.
BMC Infect Dis. 2016; 16(1): 565.
Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015.
Mera J, Vellozzi C, Hariri S, Carabin H, Drevets DA, Miller A, Reilley B, Essex W, Gahn D, Lyons L, Leston J, Ward JW.
MMWR Morb Mortal Wkly Rep. 2016; 65(18): 461-466.
Requirements for global elimination of hepatitis B: a modelling study.
Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB.
Lancet Infect Dis. 2016; 16(12): 1399-1408.
Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study.
Norder H, Karlsson M, Mellgren Å, Konar J, Sandberg E, Lasson A, Castedal M, Magnius L, Lagging M.
J Clin Microbiol. 2016; 54(3):549-55. doi: 10.1128/JCM.02343-15.
Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. 591 kB (.pdf)
Orlando Mayorga, Silja Bühler, Veronika K. Jaeger, Seraina Bally, Christoph Hatz, Gert Frösner, Ulrike Protzer, Pierre Van Damme, Matthias Egger and Christian Herzog.
JID; 2016, 214:1498-1506
Time trends in pediatric hospitalizations for hepatitis A in Greece (1999-2013): Assessment of the impact of universal infant immunization in 2008.
Papaevangelou V, Alexopoulou Z, Hadjichristodoulou C, Kourlamba G, Katsioulis A, Theodoridou K, Spoulou V, Theodoridou M.
Hum Vaccin Immunother. 2016;12(7):1852-6. doi: 10.1080/21645515.2016.1151589.
Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.
Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos G, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičič M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A.
J Viral Hepat. 2016; Suppl 1:1-12. doi: 10.1111/jvh.12493.
Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.
Poiteau L, Soulier A, Rosa I, Roudot-Thoraval F, Hézode C, Pawlotsky JM, Chevaliez S.
J Viral Hepat. 2016; doi: 10.1111/jvh.12501.
Markers for Ongoing or Previous Hepatitis E Virus Infection Are as Common in Wild Ungulates as in Humans in Sweden.
Roth A, Lin J, Magnius L, Karlsson M, Belák S, Widén F, Norder H.
Viruses. 2016;8(9). pii: E259.
Hepatitis C virus outbreak in a haemodialysis unit: learning from failures.
Senatore S, Galli C, Conti A, Faccini M, Cantoni S, Ciconali G, Mainardi G, Lamberti A, Dighera R, Radice Trolli F, Oggioni C, Angelini Sironi L, Cozzolino M, Zanetti AR, Romanò L.
J Hosp Infect. 2016; 94(3): 249-252.
Acute Hepatitis B After the Implementation of Universal Vaccination in Italy: Results From 22 Years of Surveillance (1993-2014).
Tosti ME, Alfonsi V, Lacorte E, Mele A, Galli C, Zanetti AR, Romanò L; SEIEVA Collaborating Group.
Clin Infect Dis. 2016; 62(11): 1412-1418.
Long-term Protection After Hepatitis B Vaccine.
Van Damme P.
J Infect Dis. 2016; pii: jiv750. [Epub ahead of print] No abstract available.
County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States.
Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, Jones CM, Flanagan BE, Siddiqi AE, Iqbal K, Dent AL, Mermin JH, McCray E, Ward JW, Brooks JT.
J Acquir Immune Defic Syndr. 2016; 73(3): 323-331.
Building the evidence base to eliminate hepatitis B and C as public health threats.
Ward, J. W.
Lancet Infect Dis. 2016; 16(12): 1314-1316.
Global Elimination of Hepatitis C Virus.
Ward, J. W.
Gastroenterol Hepatol (N Y). 2016; 12(10): 632-635.
Strategies for Expanding Access to HBV and HCV Testing and Care in the United States: The CDC Hepatitis Testing and Linkage to Care Initiative, 2012-2014.
Ward, J. W.
Public Health Rep. 2016; 131 Suppl 2: 1-4.
The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts.
Wiktor, S. Z. and Y. J. Hutin
Lancet. 2016; 388(10049): 1030-1031.
Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
Weir A, McLeod A, Innes H, Valerio H, Aspinall EJ, Goldberg DJ, Barclay ST, Dillon JF, Fox R, Fraser A, Hayes PC, Kennedy N, Mills PR, Stanley AJ, Aitken C, Gunson R, Templeton K, Hunt A, McIntyre P, Hutchinson SJ.
Drug Alcohol Depend. 2016;165:53-60. doi: 10.1016/j.drugalcdep.2016.05.012.

Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.

Parrón I, Planas C, Godoy P, Manzanares-Laya S, Martínez A, Sala MR, Minguell S, Torner N, Jané M, Domínguez A; Working Group for the Study of Hepatitis A in Catalonia.

Hum Vaccin Immunother. 2017 Feb;13(2):423-427. doi: 10.1080/21645515.2017.1264798. Epub 2016 Dec 7.


Serological survey of hepatitis B immunity in healthcare workers in Catalonia (Spain).

Domínguez A, Urbiztondo L, Bayas JM, Borrás E, Broner S, Campins M, Costa J, Esteve M; Working Group for the Study of the Immune Status in Healthcare Workers of Catalonia.

Hum Vaccin Immunother. 2017 Feb;13(2):435-439. doi: 10.1080/21645515.2017.1264791. Epub 2016 Dec 27.